Establishment and predictive value of an early warning system for recurrence after radical resection of BCLC stage 0/A hepatocellular carcinoma

Sheng LIU; Haoyou TANG; Yang YANG; Xin ZENG; Xiaobin HUANG; Qiuhong GU; Jianshui LI

doi:10.3969/j.issn.1001-5256.2021.09.022

Volume 37 Issue 9

Sep. 2021

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2021 > 37(9): 2113-2119

PDF( 2961 KB)

Establishment and predictive value of an early warning system for recurrence after radical resection of BCLC stage 0/A hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2021.09.022

1.
Second Department of Hepatobiliary Surgery, Affiliated Hospital of Chuanbei Medical College, Nanchong, Sichuan 637000, China
2.
Department of Critical Care Medicine, Deyang People's Hospital, Deyang, Sichuan 618000, China

Research funding:

The 2019 Scientific Research Project of City-University Cooperation in Nanchong Bureau of Science & Technology of Sichuan Province (18SXHZ0332)

Received Date: 2021-01-05
Accepted Date: 2021-03-01
Published Date: 2021-09-20

Abstract

Abstract

Objective To establish an Early Warning System for Recurrence Scoring after Radical Resection of BCLC stage 0/A Primary Liver Cancer (PLC-EWSPRS), and to investigate its predictive value. Methods A retrospective analysis was performed for the clinical data of 232 patients with BCLC stage 0/A liver cancer who underwent radical resection in Affiliated Hospital of Chuanbei Medical College from January 2009 to January 2015, and according to the presence or absence of recurrence within 5 years after surgery based on telephone or outpatient follow-up data, the patients were divided into recurrence group with 103 patients and non-recurrence group with 129 patients. The t-test was used for comparison of normally distributed continuous data between groups, and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between groups; the chi-square test or Fisher's exact test was used for comparison of categorical data between groups. The indices with statistical significance were included in the binary logistic regression analysis to investigate the risk factors for recurrence of BCLC stage 0/A liver cancer after surgery. Two points were assigned for independent risk factors and one point was assigned for risk factors to establish the PLC-EWSPRS system. The receiver operating characteristic (ROC) curve and the area under the ROC curve (AUC) were used to evaluate the diagnostic efficiency of this system. Results Compared with the non-recurrence group, the recurrence group had significantly higher levels of aspartate aminotransferase and alanine aminotransferase (ALT) and a significantly lower level of albumin (Alb) before surgery (Z=3.864 and 4.587, t=-5.628, all P < 0.001), as well as a significantly higher proportion of patients with positive HBsAg, capsular invasion, microvascular invasion (MVI), tumor diameter ≥5 cm, liver cirrhosis (moderate-to-severe), non-R0 resection, or death within 5 years (χ²=35.539, 22.325, 13.398, 7.130, 4.312, 4.034, and 18.527, all P < 0.05). The regression analysis showed that preoperative Alb < 40 g/L (odds ratio [OR]=5.796, P < 0.001), preoperative ALT ≥40 U/L (OR=3.029, P=0.002), MVI (OR=3.981, P=0.003), positive HBsAg (OR=7.829, P< 0.001), capsular invasion (OR=5.357, P< 0.001), and non-R0 resection (OR=3.048, P=0.018) were independent risk factors for recurrence of BCLC stage 0/A liver cancer within 5 years after surgery. According to the assignment criteria of the PLC-EWSPRS system, the recurrence group had the lowest score of 2 points and the highest score of 14 points, while the non-recurrence had the lowest score of 0 point and the highest score of 11 points, and the recurrence group had a significantly higher score than the non-recurrence group (P < 0.05). The ROC curve analysis showed that the PLC-EWSPRS system had an AUC of 0.918 (95% confidence interval [CI]: 0.883-0.953, P < 0.001) in predicting recurrence within 5 years after surgery in patients with BCLC stage 0/A liver cancer undergoing radical resection, and subgroup analysis showed that the system had an AUC of 0.796 (95% CI: 0.695-0.896, P=0.002), 0.859 (95% CI: 0.791-0.927, P < 0.001), and 0.944 (95% CI: 0.839-1.000, P=0.044), respectively, in predicting recurrence within 5 years after surgery in patients with a low score of 0-5 points, a moderate score of 6-10 points, and a high score of 11-14 points. Conclusion The PLC-EWSPRS system has a good value in predicting the recurrence of BCLC stage 0/A liver cancer within 5 years after surgery and thus has important guiding significance for postoperative reexamination and treatment strategy for patients with BCLC stage 0/A liver cancer undergoing radical resection.
- Carcinoma, Hepatocellular,
- Hepatectomy,
- Recurrence,
- Risk Factors

FullText(HTML)

References(22)

References

[1]	BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492.
[2]	European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis[J]. J Hepatol, 2018, 69(2): 406-460. DOI: 10.1016/j.jhep.2018.03.024.
[3]	TSILIMIGRAS DI, BAGANTE F, SAHARA K, et al. Prognosis after resection of Barcelona Clinic Liver Cancer (BCLC) stage 0, A, and B hepatocellular carcinoma: A comprehensive assessment of the current BCLC classification[J]. Ann Surg Oncol, 2019, 26(11): 3693-3700. DOI: 10.1245/s10434-019-07580-9.
[4]	FORNER A, LLOVET JM, BRUIX J. Hepatocellular carcinoma[J]. Lancet, 2012, 379(9822): 1245-1255. DOI: 10.1016/S0140-6736(11)61347-0.
[5]	YANG WS, ZENG XF, LIU ZN, et al. Diet and liver cancer risk: A narrative review of epidemiological evidence[J]. Br J Nutr, 2020, 124(3): 330-340. DOI: 10.1017/S0007114520001208.
[6]	XU W, LIU F, SHEN X, et al. Prognostic nomograms for patients with hepatocellular carcinoma after curative hepatectomy, with a focus on recurrence timing and post-recurrence management[J]. J Hepatocell Carcinoma, 2020, 7: 233-256. DOI: 10.2147/JHC.S271498.
[7]	LIU YW, YONG CC, LIN CC, et al. Liver resection of hepatocellular carcinoma within and beyond the Barcelona Clinic Liver Cancer guideline recommendations: Results from a high-volume liver surgery center in East Asia[J]. J Surg Oncol, 2020, 122(8): 1587-1594. DOI: 10.1002/jso.26183.
[8]	TSILIMIGRAS DI, BAGANTE F, MORIS D, et al. Recurrence patterns and outcomes after resection of hepatocellular carcinoma within and beyond the barcelona clinic liver cancer criteria[J]. Ann Surg Oncol, 2020, 27(7): 2321-2331. DOI: 10.1245/s10434-020-08452-3.
[9]	KABIR T, SYN N, RAMKUMAR M, et al. Effect of surgical delay on survival outcomes in patients undergoing curative resection for primary hepatocellular carcinoma: Inverse probability of treatment weighting using propensity scores and propensity score adjustment[J]. Surgery, 2020, 167(2): 417-424. DOI: 10.1016/j.surg.2019.09.022.
[10]	Medical Administration of the National Health Commission of the people's Republic of China. Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)[J]. J Clin Hepatol, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007. 中华人民共和国国家卫生健康委员会政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 临床肝胆病杂志, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007.
[11]	YANG F, MA L, YANG Y, et al. Contribution of hepatitis B virus infection to the aggressiveness of primary liver cancer: A clinical epidemiological study in Eastern China[J]. Front Oncol, 2019, 9: 370. DOI: 10.3389/fonc.2019.00370.
[12]	WANG S, WU QW, LI XK, et al. Interpretation of guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)[J]. J Clin Hepatol, 2020, 36(5): 996-999. DOI: 10.3969/j.issn.1001-5256.2020.05.009. 王姗, 吴庆旺, 李小科, 等. 《原发性肝癌诊疗规范(2019年版)》解读[J]. 临床肝胆病杂志, 2020, 36(5): 996-999. DOI: 10.3969/j.issn.1001-5256.2020.05.009.
[13]	WU JC, HUANG YH, CHAU GY, et al. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma[J]. J Hepatol, 2009, 51(5): 890-897. DOI: 10.1016/j.jhep.2009.07.009.
[14]	WANG B, XIA CY, LAU WY, et al. Determination of clonal origin of recurrent hepatocellular carcinoma for personalized therapy and outcomes evaluation: A new strategy for hepatic surgery[J]. J Am Coll Surg, 2013, 217(6): 1054-1062. DOI: 10.1016/j.jamcollsurg.2013.07.402.
[15]	KIM JM, KWON CH, JOH JW, et al. Intrahepatic metastasis is more risky than multiple occurrence in hepatocellular carcinoma patients after curative liver resection[J]. Hepatogastroenterology, 2015, 62(138): 399-404. DOI: 10.5754/hge131006.
[16]	LIN S, YE F, RONG W, et al. Nomogram to assist in surgical plan for hepatocellular carcinoma: A prediction model for microvascular invasion[J]. J Gastrointest Surg, 2019, 23(12): 2372-2382. DOI: 10.1007/s11605-019-04140-0.
[17]	ZHANG X, LI J, SHEN F, et al. Significance of presence of microvascular invasion in specimens obtained after surgical treatment of hepatocellular carcinoma[J]. J Gastroenterol Hepatol, 2018, 33(2): 347-354. DOI: 10.1111/jgh.13843.
[18]	ROAYAIE S, BLUME IN, THUNG SN, et al. A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma[J]. Gastroenterology, 2009, 137(3): 850-855. DOI: 10.1053/j.gastro.2009.06.003.
[19]	ERSTAD DJ, TANABE KK. Prognostic and therapeutic implications of microvascular invasion in hepatocellular carcinoma[J]. Ann Surg Oncol, 2019, 26(5): 1474-1493. DOI: 10.1245/s10434-019-07227-9.
[20]	REGIMBEAU JM, ABDALLA EK, VAUTHEY JN, et al. Risk factors for early death due to recurrence after liver resection for hepatocellular carcinoma: Results of a multicenter study[J]. J Surg Oncol, 2004, 85(1): 36-41. DOI: 10.1002/jso.10284.
[21]	LAFARO K, GRANDHI MS, HERMAN JM, et al. The importance of surgical margins in primary malignancies of the liver[J]. J Surg Oncol, 2016, 113(3): 296-303. DOI: 10.1002/jso.24123.
[22]	HU W, HUANG S, DONG L, et al. MDR1 gene polymorphism correlated with pathological characteristics and prognosis in patients with primary hepatocellular carcinoma receiving interventional therapy[J]. Anticancer Drugs, 2019, 30(3): 233-240. DOI: 10.1097/CAD.0000000000000680.

Relative Articles

[1]	Zexin HU, Jiaqing LI, Wanci LI, Binyan ZHONG, Shuai ZHANG, Jian SHEN, Xiaoli ZHU. Efficacy and safety of transcatheter arterial chemoembolization combined with targeted therapy and immunotherapy in treatment of patients with stage Ⅱ‍b/Ⅲ‍a hepatocellular carcinoma based on China Liver Cancer Staging[J]. Journal of Clinical Hepatology, 2024, 40(3): 550-555. doi: 10.12449/JCH240318
[2]	Qiuju PENG, Tao DAI, Guibo XIE, Jinjun CHEN, Xiao CHENG, Yuan YAN. Research advances in transcatheter arterial chemoembolization combined with targeted agents or anti-PD-1/PD-L1 monoclonal antibody in treatment of patients with unresectable hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2023, 39(7): 1740-1746. doi: 10.3969/j.issn.1001-5256.2023.07.033
[3]	Bailu CAO, Min AI, Ping HUANG, Yongfeng YANG. Research advances in local treatment combined with systemic therapy for advanced hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2023, 39(8): 1972-1976. doi: 10.3969/j.issn.1001-5256.2023.08.031
[4]	Jing LUO, Caihong LYU, Yongping YANG. Clinical efficacy and safety of percutaneous cryoablation combined with percutaneous ethanol injection in elderly patients with hepatocellular carcinoma aged 70 years or older[J]. Journal of Clinical Hepatology, 2022, 38(2): 365-371. doi: 10.3969/j.issn.1001-5256.2022.02.021
[5]	Jun LING, Wenwu WAN, Zheng ZENG, Huihua YAO, Ou JIANG, Bing DING. Clinical effect of transcatheter arterial chemoembolization combined with microwave ablation versus repeat resection in treatment of recurrent hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(9): 2053-2060. doi: 10.3969/j.issn.1001-5256.2022.09.020
[6]	Yihan YANG, Wanci LI, Binyan ZHONG, Jian SHEN, Xiaoli ZHU. Efficacy and safety of transarterial chemoembolization combined with camrelizumab and apatinib in treatment of advanced hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(12): 2755-2760. doi: 10.3969/j.issn.1001-5256.2022.12.014
[7]	Xiaomin LIU, Wei SUN, Jianying WEI, Wendong LI, Xiaoyan DING, Minghua YU, Jinglong CHEN. Efficacy and safety of lenvatinib in patients with unresectable hepatocellular carcinoma previously treated with tyrosine kinase inhibitor[J]. Journal of Clinical Hepatology, 2022, 38(6): 1323-1327. doi: 10.3969/j.issn.1001-5256.2022.06.020
[8]	Xiaopeng DING, Jun TIE, Jiahao YU, Pengwei REN, Guoyun XUAN, Shuoyi MA, Changcun GUO, Ying HAN, Xinmin ZHOU. Efficacy and safety of programmed death-1 inhibitor combined with transarterial chemoembolization and anti-angiogenic drugs in treatment of advanced hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(5): 1086-1091. doi: 10.3969/j.issn.1001-5256.2022.05.021
[9]	Chunxia PING, Jing ZHANG, Wei ZHAO, Liang MA, Da FANG, Shichang CUI. Three-year follow-up outcomes of hepatocellular carcinoma patients undergoing liver resection versus liver transplantation[J]. Journal of Clinical Hepatology, 2021, 37(2): 343-347. doi: 10.3969/j.issn.1001-5256.2021.02.019
[10]	Yanmei ZOU, Xianglin YUAN. Application value of immunotherapy in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(8): 1758-1760. doi: 10.3969/j.issn.1001-5256.2021.08.004
[11]	Ningning ZHANG, Wei LU. Targeted therapy for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(8): 1753-1757. doi: 10.3969/j.issn.1001-5256.2021.08.003
[12]	Zhiyuan YU, Shiyu YANG, Jiaqi LI, Yan SUN. Current developmental status of non-surgical treatment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(5): 1205-1207. doi: 10.3969/j.issn.1001-5256.2021.05.048
[13]	Yisheng PENG, Pan HE, Gang ZHU, Xinkai LI, Shunde TAN, Jianfei CHEN, Jun FAN, Bin LUO, Song SU, Bo LI, Xiaoli YANG. Efficacy and safety of CalliSpheres microsphere versus conventional transcatheter arterial chemoembolization in treatment of hepatocellular carcinoma: A Meta-analysis[J]. Journal of Clinical Hepatology, 2021, 37(8): 1841-1847. doi: 10.3969/j.issn.1001-5256.2021.08.019
[14]	Lu Jian, Zhu HaiDong, Teng GaoJun, Wang Zhi. Role of interventional therapy in the downstaging of advanced liver cancer[J]. Journal of Clinical Hepatology, 2020, 36(2): 272-276. doi: 10.3969/j.issn.1001-5256.2020.02.006
[15]	Tang JinQuan, He Pan, Su Song, Luo Bin, Fang Cheng, Li Bo, Xia XianMing, Li YuWei. Short-and long-term effects of radiofrequency ablation versus minimally invasive hepatectomy in treatment of small hepatocellular carcinoma: A Meta-analysis[J]. Journal of Clinical Hepatology, 2020, 36(2): 358-362. doi: 10.3969/j.issn.1001-5256.2020.02.025
[16]	Xing AiLi, Zheng JiaSheng. Clinical effect of transcatheter arterial chemoembolization combined with local thermal ablation in treatment of large hepatocellular carcinoma and related influencing factors[J]. Journal of Clinical Hepatology, 2019, 35(1): 98-103. doi: 10.3969/j.issn.1001-5256.2019.01.018
[17]	Liang HongYuan, Guo QiYong, Mao XiaoNan, Sun Wei, Zhao Gang, Wang XiHai, Liu Zhen, Wen Feng, Lu ZaiMing. Clinical effect of sequential therapy with transarterial chemoembolization and bipolar-needle radiofrequency ablation in treatment of hepatocellular carcinoma in high-risk locations[J]. Journal of Clinical Hepatology, 2018, 34(7): 1462-1469. doi: 10.3969/j.issn.1001-5256.2018.07.020
[18]	Wang HuaMing. The interventional treatment for hepatocellular carcinoma originating from the caudate lobe[J]. Journal of Clinical Hepatology, 2016, 32(1): 68-71. doi: 10.3969/j.issn.1001-5256.2016.01.010
[19]	Sun Wei, Ding XiaoYan, Chen JingLong. Clinical effect and safety of percutaneous radiofrequency ablation following transcatheter arterial chemoembolization in treatment of primary liver cancer in high-risk locations[J]. Journal of Clinical Hepatology, 2016, 32(12): 2337-2341. doi: 10.3969/j.issn.1001-5256.2016.12.021
[20]	Zhu XiaoLi, Shen Jian. Application of local ablative therapies for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2016, 32(1): 56-61. doi: 10.3969/j.issn.1001-5256.2016.01.008

Supplements(0)

Cited By

Cited by

Periodical cited type(6)

1.	杨晨，余上海，徐飞鹏，张华. 磁共振质子密度脂肪分数（MRI-PDFF）在肝脂肪定量中的应用. 临床肝胆病杂志. 2024(03): 600-605 . 本站查看
2.	刘建宪，王振松，王鑫，田宁，陈鹏，于丹，杨燕兴，程传力，邹超，甘洁. 基于5.0T MRI定量肝脏质子密度脂肪分数. 中国医学影像技术. 2024(05): 671-676 .
3.	贺小红，洪居陆，高明勇，吴李贤，杨镜全. 两种场强磁共振IDEAL-IQ序列对质子密度脂肪分数和铁含量定量分析的初步对比研究. 国际放射医学核医学杂志. 2023(03): 148-154 .
4.	宋玥锦，王凯，牛宏伟，王春生. 影像学检查方法在非酒精性脂肪性肝病定量分析中的应用. 影像技术. 2023(03): 69-74 .
5.	栗雯霏，张捷，栗建辉. 影像技术对非酒精性脂肪肝的评价. 肝脏. 2023(07): 875-880 .
6.	黄江水，文建荣，宋国军，蒋小龙，李伟，王敏，唐艳芬. MRI-PDFF降低对非酒精性脂肪性肝病患者肝纤维化预测研究. 影像研究与医学应用. 2022(23): 69-71 .

Other cited types(3)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(2) / Tables(4)

Get Citation

PDF

XML

Article Metrics

Article views (574) PDF downloads(46)

Establishment and predictive value of an early warning system for recurrence after radical resection of BCLC stage 0/A hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2021.09.022